

Injectable Biologics Adult Patient Referral Form

Patient Demographics Information

Patient Name		SSN#	DOB
Patient Address			
Primary Phone	Cellular Phone	Work Phone	
Emergency Contact Name, Relationship		Emergency Contact Phone Number	

Additional Documentation Needed

- Copy of insurance cards	- History and Physical with patient demographics	- Recent vitals including blood pressure
---------------------------	--	--

Patient Insurance Information

Insurance Plan #1		Insurance Plan #2	
Subscriber Name	DOB	Subscriber Name	DOB
Policy Number	Group ID	Policy Number	Group ID

Patient Clinical Information

Gender	Height (in.)	Weight (lbs)	Allergies (food/drug)
--------	--------------	--------------	-----------------------

Statement of Medical Necessity / Primary Diagnosis

ICD10:	Description of diagnosis:
--------	---------------------------

Medication Information/Prescription and Orders

Medication:	Dosage Form:	Dose and Directions:
☐ Fasenra (benralizumab)	☐ 30 mg/mL single dose autoinjector pen ☐ 10 mg/0.5 mL single dose prefilled syringe	☐ Severe Eosinophilic Asthma: 30 mg SubQ every 4 weeks X 3 doses, then every 8 weeks thereafter ☐ Eosinophilic Granulomatosis w/ Polyangiitis: 30 mg SubQ every 4 weeks
☐ Nucala (mepolizumab)	☐ 40 mg/0.4mL prefilled syringe ☐ 100 mg/mL prefilled syringe ☐ 100mg/mL prefilled autoinjector	☐ Severe Asthma: 100 mg SubQ every 4 weeks ☐ Chronic Rhinosinusitis w/ Nasal Polyps (CRwNP): 100 mg SubQ every 4 weeks ☐ Eosinophilic Granulomatosis w/ Polyangiitis: 300 mg (3 separate 100 mg injections) SubQ every 4 weeks ☐ Hypereosinophilic Syndrome: 300 mg (3 separate 100 mg injections) SubQ every 4 weeks
☐ Xolair (omalizumab)	☐ 75 mg/0.5 mL ☐ prefilled ☐ 150 mg/1 mL syringe ☐ 300 mg/2 mL ☐ autoinjector	☐ Asthma: _____ mg SubQ every 2 weeks OR _____ mg SubQ every 4 weeks ☐ Chronic Rhinosinusitis with Nasal Polyps: _____ mg SubQ every 2 weeks OR _____ mg SubQ every 4 weeks ☐ Chronic Spontaneous Urticaria: _____ mg SubQ every 4 weeks ☐ IgE-Mediated Food Allergy: _____ mg SubQ every 4 weeks OR _____ mg SubQ every 2 weeks
☐ Dupixent (dupilumab)	☐ 200 mg/1.14 mL prefilled syringe ☐ 300 mg/2 mL prefilled syringe ☐ 200 mg/1.14 mL prefilled pen ☐ 300 mg/2 mL prefilled pen	Asthma: ☐ Loading dose: 400 mg (2-200 mg injections) SubQ X1, Maintenance dose: 200 mg SubQ every 2 weeks ☐ Loading dose: 600 mg (2-300 mg injections) SubQ X1, Maintenance dose: 300 mg SubQ every 2 weeks Atopic Dermatitis: ☐ Loading dose: 600 mg (2- 300 mg injections) SubQ X 1; Maintenance dose: 300 mg SubQ every other week Bullous Pemphigoid: ☐ Loading dose: 600 mg (2- 300 mg injections) SubQ X 1; Maintenance dose: 300 mg SubQ every other week Eosinophilic Esophagitis: ☐ 300 mg SubQ every week Refractory COPD: ☐ 300 mg SubQ every other week Chronic Rhinosinusitis w/ Nasal Polyps ☐ 300 mg SubQ every other week Chronic Spontaneous Urticaria: ☐ Loading dose: 600 mg (2- 300 mg injections) SubQ X 1; Maintenance dose: 300 mg SubQ every other week Prurigo Nodularis ☐ 600 mg SubQ X 1, then 300 mg every other week

Quantity/Refills

Dispense Quantity #QS + 1 year of refills unless otherwise noted	*If subsequent treatment only Date of last injection_____ Next dose due _____
--	--

- Severe reaction (w/breathing problems): CALL 911, administer Epinephrine 0.3 mg IM or 0.15 mg, #2 (as determined by patient weight)

Prescriber Information

Prescriber Name	Office Contact	NPI#	License#
Practice Address		Practice Phone	Practice Fax
Prescriber Signature Required - Substitution Permitted	Date	Prescriber Signature Required - Dispense as Written	Date